Immuneering Corporation
NASDAQ:IMRX · NASDAQ Global Market
-$0.01 today
Vol 1.00M · Avg 1.38M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-25.6%
avg -15.1%
ROIC
-26.7%
avg -55.4%
ROA
-24.2%
avg -50.4%
Analysis
ROA is currently the strongest return metric at -24.2% versus its period average of -50.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Benjamin J. Zeskind | Co-Founder, President, Chief Executive Officer & Director | $1.08M | — | 43 | $33,350.00 | 0.09% |
Brett Hall | Chief Scientific Officer | $999,752.00 | — | 57 | $382,531.00 | 1.05% |
Michael D. Bookman | Chief Legal Officer & Secretary | $757,560.00 | — | 39 | $176,000.00 | 0.48% |
Igor Matushansky | Chief Medical Officer | $656,780.00 | — | 53 | $140,000.00 | 0.39% |
Harold E. Brakewood | Chief Business Officer | $579,769.00 | — | 60 | $140,000.00 | 0.39% |
Robert J. Carpenter | Co-Founder & Chair Emeritus | $45,000.00 | — | 80 | $33,350.00 | 0.09% |
Paula George | Director of Accounting & Operations and Assistant Corporation Controller | — | — | — | — | — |
Peter King | Head of Discovery & Vice President | — | — | — | $33,350.00 | 0.09% |
Leah R. Neufeld | Chief People Officer | — | — | 54 | $29,598.00 | 0.08% |
Courtney Dugan | VP and Head of Investor Relations & Corporate Communications | — | — | — | — | — |
Mallory Morales | Senior VP of Finance, Chief Accounting Officer & Treasurer | — | — | 42 | $140,000.00 | 0.39% |
Praveen Nair | Head of Translational Pharmacology & Vice President | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
19
$518,654.95
Sells
0
$0.00
Net Sentiment
+$518,654.95
Net buying
Most Active
Feinberg Peter
4 transactions
1–10 of 19
Analysis
Insiders reported 19 buys worth $518,654.95 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $518,654.95. Feinberg Peter was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Assembly Biosciences, Inc.
NASDAQ:ASMB
$388.47M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$293.92M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$278.94M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$267.28M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$243.08M
Zura Bio Limited
NASDAQ:ZURA
$241.50M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$212.32M
Humacyte, Inc.
NASDAQ:HUMA
$157.32M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$127.03M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$117.89M
Who manages IMRX?
Immuneering Corporation (IMRX) lists 12 active executives. The top listed executive is Brett Hall, Chief Scientific Officer.
Are IMRX insiders buying or selling?
Recent insider activity shows net buying of $29.45M.
Explore More
Continue the stock analysis
Jump to another research area for this company.